Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells

Xue Xiao 1,4,5,8,10†, Juan Zou 3†, Yin Fang 4†, Yibo Meng 7,1, Chao Xiao 9, Jiaxin Fu 1,5, Shiyu Liu 1,2, Peng Bai 6*, and Yuan Yao 1,2*

Abstract

Background: The anti-tumor activities of Natural compounds and their derivatives are of great interest to pharmaceutical industries. Fisetin is one of prospective natural compounds in this regard but unfortunately with poor hydrophilicity.

Methods: The effects of unmodified and modified fisetin in cultured ovarian cancer cells were compared by transmission electronmicroscopy to determine apoptotic bodies, MTT assay to quantitate cell numbers, and fluorescence activated cell sorting analyse of various markers to determine the apoptotic state. In addition, the efficacy of fisetin and fisetin-micelles in vivo was determined by using immunocompromised mice. Apoptosis was measured by established markers using both western blot analysis and immunohistochemistry. Angiogenesis in a xenograft mouse model carrying SKOV3 cells was evaluated by color Doppler ultrasound and immunohistochemistry.

Result: Multiple lines of evidence indicated that fisetin and fisetin micelles induce apoptosis in ovarian cancer cells in a dose-dependent manner. Histological analysis, terminal deoxynucleotidyltransferase-mediated nick-end labeling assay, western blot, immunohistochemical detection and microvessel density detection demonstrated that fisetin and fisetin micelles induced increased tumor apoptosis, proliferation suppression and antiangiogenesis activities.

Conclusion: As far as we know, the present study is the first time to demonstrate the potency of both fisetin and fisetin micelles inducing apoptosis in ovarian cancer cells. Further studies will be needed to validate the therapeutic potential of fisetin and fisetin micelles in ovarian cancer treatment.

Keywords: Ovarian cancer, Fisetin, Polymeric micelles encapsulating fisetin, Apoptosis, Antitumor, Mitochondrial pathway

Background

Ovarian cancer has been the leading cause of cancer-related death for women in the past 15 years. In 2017, about 22,440 women have been diagnosed with ovarian cancer and 14,080 have been died from the disease in USA alone. In the absence of an effective early diagnosis, approximately 70% patients are already diagnosed with stage III or IV of ovarian cancer [1]. Taxol/platinum-based chemotherapies were still identified as the most standard and widely used chemotherapy. Other novel, targeted therapies such as PARP, VEGF and proteasome inhibitors, resulting in a dismal 25% five-year OS (overall survival) as well as 70% recurrence [2]. Therefore, identification of novel therapeutic targets and treatment regimens is subjected to intensive research.

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is an attractive candidate for ovarian cancer treatment. Previous studies have showed that fisetin exhibits antitumor effect through various mechanisms [3–7]. Previous studies have found...
that fisetin has antioxidant [8, 9], anti-inflammatory [10], anti-
cell proliferation [11–13], anti-tumor metastasis [14], anti-
angiogenesis [15–17], anticancer [16], anti-allergy [18], anti-platelet functions [19]. However, the poor water
solubility of fisetin (less than 1 mg/g) retarded the clinical
application and commercial production. In current study,
we detected the effect of fisetin and fisetin-micelles on
ovarian cancer cell line growth, the relative apoptosis
pathway and the anti-tumor effect in xenograft mice. The
aim is to find new effective and low toxic drugs for treat-
ment of ovarian cancer. Recently, the biodegradable poly-
meric micelles are gradually gaining attention due to high
bioavailability, better selectivity and accurate targeting in
the form of drug delivery systems. Polymeric copolymers
are self-assembled amphiphilic particles, where the hydro-
phobic blocks hind the hydrophobic drugs in the central,
the hydrophilic blocks can form a shell to contact with
aqueous solvent [20]. Theoretically, nanosized particles
and increased water solubility possess increased antitumor
activity and passive targeting. Moreover, the tension
effects in tumor tissues and sustained release mechanism
in blood vessels can enlarge their antitumor ability.

In this study, we used monomethyl poly (ethylene gly-
col)-poly(ε-caprolactone), MPEG-PCL polymeric micelles
to modify the physical properties of fisetin. The histological
analysis, terminal deoxynucleotidyltransferase-mediated
nick-end labeling assay, western blot, immunohistochemi-
detection and microvessel density detection were used
to investigate the antitumor activity of fisetin and fisetin
micelles both in vitro and in vivo.

Methods

Materials

Fisetin, purification is more than 98%, was provided by
the Department of Pharmacology of Sichuan University
(Chengdu, Sichuan, China). Monomethyl poly (MPEG,
Mn = 2000, Fluka, USA); ε-caprolactone (ε-CL, Alfar
Aesar, USA), stannous octoate (Sn(Oct)2, Sigma, USA)
MPEG-PCL copolymer was synthesized according to our
previous work in State Key Laboratory. The copolymers
were characterized by1H NMR with molecular weight
3950.SKOV3 human ovarian cancer cell line was pro-
vided by Laboratory of Genetics, West China Second
University Hospital, RPMI-1640 and fetal bovine serum
(FBS) (Gibco BRL, Life Technologies Gaithersburg, MD,
USA). Thiazolyl blue (sigma company), VEGF was
obtained from (R&D Systems, Minneapolis, MN). VEGF
ELISA kit was purchased from R&D Systems (Minneapolis,
MN). Growth factor–reduced Matrigel was from BD Bio-
sciences (San Jose, CA, USA). Antibodies against VEGF,
VEGFR2, Bcl-2, and Bcl-xL were obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). β-actin anti-
body was purchased from Sigma Chemical Co. (St. Louis,
MO, USA).CD31 antibodies were from EpitomicsInc
(Burlingame,CA, USA). Flow cytometry analyzer (Beckman
Coulter), Hitachi h-600IV TEM (West China School of
Preclinical and Forensic Medicine, Sichuan University).
Inverted biological microscope (Chongqing Photoelectric
instrument Co, Ltd., XDS-1B), Cell culture box (SANYO,
Japan MCO-18 M (UV)), Standard ultra clean bench (SW-
CJ-2FD, AIRTECH).

Cell lines and cell culture

SKOV3 cells, human bronchial cells, vascular smooth
muscle cells, OSE, HEC-1A, CASKi and HepG2cells
were cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum at 37 °C under a humidified
95%:5% (v/v) mixture of air and CO2. When the SKOV3
cells in the culture box covered 70–80% of the bottle,
digested with trypsin, collection and centrifugation. Cells
in logarithmic growth phase were used in the experi-
ment. All the cells were bought from ATCC (American
type culture collection), the partial are primary cells.

Transmission electron microscopy (TEM)

SKOV3 cells were treated with 100 μmol/L fisetin and
fisetin micelles for 24 h. Cells were digested with trypsin
after centrifuged and harvested in 2 ml EP tube, centri-
fuge for 15 min with 2000 rpm, the supernatant was dis-
carded. Cells then fixed in 5% glutaraldehyde and 3%
paraformaldehyde, dehydrated in an ascending acetone
series, embedded in Epon812 resin, sectioned into ultra-
thin longitudinal sections, and imaged using a transmis-
sion electron microscope (JEOL 1010, Jeol, Tokyo, Japan).

Fisetin and fisetin micelles treatment and determination
of cell survivability

Cells were seeded at a density of 5 × 103 per well in 96-
well tissue culture plates after digested with trypsin and
diluted with 10% fetus RPMI-1640 culture. Carrier
DMSO was used as a negative control. The cultured
cells were treated with fisetin and fisetin micelles on dif-
f erent doses(10 μmol/L, 30 μmol/L, 100 μmol/L and
300 μmol/L respectively). Viability of each cell groups
was examined by the3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT; Sigma, USA) assay
every 24 h. Time- and dose-dependent curve of fisetin/
fisetin micelles-treated cells were generated. The cyto-
toxic effects of fisetin/fisetin micelles were expressed as
the IC50 (half maximal inhibitory concentration) or TGI
(total growth inhibiting concentration). Formula IgIC50 =
Xm-1(P-(3-Pm-Pn)/4) was used to calculate IC50.

Flow cytometry analysis for apoptosis

Flow cytometry was used to analyze the loss of mem-
brane symmetry and membrane integrity using FITC
Annexin V and propidium iodide (BD ApoAlertAnnexin
V–FITC Apoptosis, kit, BD Biosciences), respectively.
Briefly, cells were treated with fisetin and fisetin micelles at various concentrations (30 μmol/L, 100 μmol/L and 300 μmol/L) for 48 h. Cells then were digested with non-EDTA trypsin for 3 min and harvested. 5 × 10⁶ Cells were labeled with propidium iodide (PI) and Annexin V-FITC for 30 min at room temperature. After filtration with a 300 dialyzer (FACSort, Becton Dickinson, San Jose, CA). Data were further analyzed by CellQuest software, version 3.1 (Becton Dickinson and ModFit LT 3.2 (Verity Software House). Experiments were conducted in triplicate.

**Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay**

Cells layers with different dose- and time-treated were fixed with 4% paraformaldehyde solution for 15 min at room temperature, washed with phosphate buffered saline, and then permeated with permeabilization solution (Triton X-100, 0.1% and sodium citrate) at 4 °C for 2 min. Fisetin-treated SKOV3 cells and control were labeled with the TUNEL reaction mixture for 1 h at 37 °C. Images were taken by fluorescence microscopy. (Confocal Scanning Laser Microscopy, Leica TCS4D, Germany).

**Western blotting analysis**

SKOV3 cells were treated with fisetin/fisetin micellesat various concentrations(30 μmol/L, 100 μmol/L, and 300 μmol/L) at 24 h time point. Whole cell lysates were obtained using RIPA Buffer (Sigma, USA). The protein concentrations were determined using the Bradford assay. In each lane, 25 mg proteins were resolved in 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Antibodies (anti-Bcl-2 (1:1000), anti-Bax (1:2000), anti-procaspase-9 (1:1000), anti-caspase-9 (1:1000), anti-procaspase-3 (1:1000), anti-caspase-3 (1:2000) and PARP (1:2000)) incubated the membrane as primary antibodies and HRP-conjugated secondary antibodies were used sequentially. Blots were developed with enhanced chemiluminescence (ECL, Pierce, USA) and exposed to X-ray film.

**The effect of fisetin and fisetin micelles in a xenograft model of ovarian cancer**

To investigate if fisetin/fisetin micelles can inhibit tumor growth in vivo, we established a xenograft model of SKOV3 cells in BALB/athymic nude mice. SKOV3 cells were digested, harvested and concentrated, then washed and resuspended with new PBS and made the final concentration of cells to be 5 × 10⁶/L. As the model described previously [21, 22], totally 40 4- to 6-week-old female Balb/c nude mice were injected with 5 × 10⁶ SKOV3 cells, led to tumor growth up to 1 week and randomly divided into 8 groups (n = 5). Mice bearing tumors were injected with fisetin or fisetin micelles. Mice were injected once every week starting on day 0 for 4 times. Control groups were treated with vehicle (DMSO, <0.1%) in saline solution or treated with mPEG-PCL. General observations of the mice were made twice weekly. Two perpendicular diameters of the xenograft in centimeters were measured to calculate the tumor mass using the formula (a × b²)/2. All experiments were conducted according to the guidelines of The Institute for Nutritional Sciences (Shanghai, China).

**Statistical analysis**

Statistical significance of differences between groups was performed using the Student’s t-test. Data are presented as mean ± standard deviation (SD). IC50 values were calculated by SPSS (Solutions Statistical Package for the Social Sciences) software version 13.0 (SPSS, Inc., China). A value of p ≤ 0.05 was considered to be significance. A random number table method was used to make a random grouping, as shown in Table 1.

**Results**

**Fisetin and Fisetin micelles treatment inhibits growth of human ovarian cancer cells**

The chemical structure of fisetin and fisetin micelles is shown in Fig. 1a. The fisetin micelles was prepared according to previous methods, which self-assemble into structures of hydrophilic shells and hydrophobic cores. The average size, polydispersion index, encapsulating efficiency, and drug loading of fisetin micelles were 22.4 ± 3.0 nm, 0.163 ± 0.032, 98.53 ± 0.02%, and 9.88 ± 0.14%, respectively. To investigate the cytotoxic effects of fisetin/fisetin micelles on human ovarian cancer cells, we first treated SKOV3 cells with increasing concentrations of fisetin/fisetin micelles and examined the anti-proliferation effect after 24, 48, 72 and 96 h. As shown in Fig. 1, cell numbers were reduced after fisetin/fisetin micelles treatment in a time- and dose-dependent manner in SKOV3 ovarian cancer cells but not in normal cell lines, including human bronchial epithelial cells, human ovarian surface epithelial cells, human vascular smooth muscle cells, etc. At a concentration of 100 μM, the inhibition index of 7-day fisetin-treatment was 83.0%, slightly lower than PSI and etoposide, well known cytotoxic agents. The cell survival curves of the three cancer cell lines (CASKi, HEC-1A and HepG2) after fisetin-treatment or fisetin micelles-treatment for 4 days indicated >50% inhibition ratio compared to untreated groups. More specifically, the IC50S for fisetin in tumor derived cell lines CASKi, HEC-1A and HepG2 were 114.8 μM, 108.9 μM, 126.8 μM respectively. The IC50 and TGI values of fisetin on treated SKOV3 cells were 61.2 μM and 34.8%. The IC50 and TGI values of fisetin micelles on treated SKOV3 cells were 48.2 μM and 48.7%. Furthermore, prolonged exposure time and increased drug dose vastly increased its inhibitory effect on cell number.
Characterization of Fisetin-induced apoptosis in ovarian cancer cells from transmission electron microscopy results
To determine the apoptotic features induced by fisetin/fisetin micelles treatment, we carried out analysis using several independent approaches. Firstly, we used transmission electron microscopy to check the apoptotic bodies. Secondly, we utilized terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay to indicate the apoptosis of fisetin/fisetin micelles-treated SKOV3 cells. Thirdly we verified our conclusion depending on western blot results.

After 12 h of fisetin/fisetin micelles treatment, ovarian cancer cells shrunk, followed by cell detachment from the culture plate surface indicating anoikis. Transmission electron microscopy of fisetin/fisetin micelles-treated SKOV3 cells demonstrated ultrastructural morphological changes characteristic of apoptosis. Figure 2Ab showed the well-defined, uniform and dense chromatin under the nuclear membrane. Figure 2Ac showed changes in the kernel. The chromatin of the nucleus condensed into a heterologous particle and located in the center of the nucleus. The

Table 1 Groups of Xenograft model of ovarian cancer and treatment

| Groups | Mice number | Drug treatment | Concentration and dosage | Frequency | weeks |
|--------|-------------|----------------|--------------------------|-----------|-------|
| Group A | 5 | NS + DMSO | control 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group B | 5 | mPEG-PCL + DMSO | control 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group C | 5 | fisetin + mPEG-PCL + DMSO | 50 mg/kg, 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group D | 5 | Fisetin micelles + mPEG-PCL + DMSO | 100 mg/kg, 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group E | 5 | NS + DMSO | control 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group F | 5 | mPEG-PCL + DMSO | control 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group G | 5 | fisetin + mPEG-PCL + DMSO | 50 mg/kg, 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
| Group H | 5 | Fisetin micelles + mPEG-PCL + DMSO | 100 mg/kg, 0.1 ml | Treatment 5 days and rest 2 days | 2 weeks |
Changes inside the cytoplasm including cytoskeletal filaments intensive, nuclear protein paritcle swarms, endopalsmic reticulum rearrangement and form concentric circle shape in cells. DNA fragmentation assay showed oligonucleosomal DNA ladders in Fisetin-treated cells (Data not shown). The results of TUNEL staining research verified that Fisetin/fisetin micelles induced apoptosis in SKOV3 cells and furthermore, showed that Fisetin/fisetin micelles induced apoptosis in SKOV3 cells in a dose-dependent manner (Fig. 2).
To quantitate apoptotic process, fluorescence activated cell sorting (FACS) analysis was carried out to detect early apoptosis marked by Annexin V and late apoptosis by PI. SKOV3 Cells treated with various concentrations (30 μM, 100 μM, 300 μM) for 24 were subjected to analysis. To further analyze cell death induced by fisetin and fisetin micelles, the relative portions of DNA contents were assessed by flow cytometry. In Fig. 3a, the left lower quadrant of the Annexin showed alive cells (Annexin V-/PI-), and the right upper quadrant of Annexin indicated the apoptotic cells in the late stage (Annexin V+/PI+), and the right lower quadrant was the early apoptotic cells (Annexin V+/PI-). Flow cytometry annexin V/PI staining showed that the early apoptosis of SKOV3 cells treated with 300 μmol/L of festin (73.4%) at 24 h was obviously higher than cells treated with 100 μmol/L of festin(31.2%). The late-stage apoptosis of SKOV3 cells treated with 300 μmol/L of festin (15.6%) at 24 h was obviously higher than cells treated with 100 μmol/L of festin(36.0%). Concentration-dependent studies indicated an apoptosis ratio increasing compared to the control group after 24 h treatment. The similar results were shown in flow cytometry data of fisetin micelles treated SKOV3 cells. SKOV3 cells treated with multiple concentrations were analyzed. The results showed that fisetin micelles treatment induced SKOV3 cell apoptosis in a concentration-dependent manner. The apoptosis ratio is higher in fisetin-micelle treated cells, indicating a better drug kinetics (Fig. 3).

**Fisetin/fisetin micelles activate the apoptosis through mitochondrial pathway**

We analyzed the sub-routes of both fisetin-induced and fisetin micelles-induced apoptosis. Fisetin activated the apoptosis by mitochondrial pathway. As shown in Fig. 4, fisetin treatment led to high expression of proapoptotic protein Bax followed by activation of Caspase-3 and Casapse-9 in a concentration-dependent manner. Pro-caspase-3 and pro-caspase-9 gradual disappeared concomitant with appearance of proteolytic cleavage bands. The downstream factors such as cytochrome c and PARP proteins levels were markedly increased in a concentration-dependent manner. Anti-apoptotic Bcl-2 protein levels were reduced in cells treated with fisetin at a concentration as low as 10 μM. Similarly, the imbalance of Bax/Bcl-2 appeared in SKOV3 cells treated with fisetin micelles. The results were verified by the immunochemical studies. The slides indicated fisetin/fisetin micelles broke the balance of Bax and Bcl-2. The same results were observed in the fisetin micelles-treated SKOV3 cells.

**Fisetin/fisetin micelles inhibit the tumor growth in a xenograft mouse model**

The antitumor efficacy of both fisetin and fisetin micelles was determined in vivo. SKOV3 cells treated with different dose of fisetin/fisetin micelles (50 mg/kg) with DMSO and mPEG-PLC were taken as control, then were injected into well-established xenograft mouse model of ovarian cancer. Tumor growth was monitored every other day. No acute toxic effects were observed during the experiment process. Interestingly, the tumor volume in fisetin-treated groups was obviously smaller than the other control groups, which treated with vehicle solution of DMSO (< 0.01%) diluted in saline solution (p > 0.05). Highest dose of fisetin-treated groups showed strongest tumor inhibition ability; the difference was statistically significant, which indicated that fisetin treatment significantly delayed ovarian cancer growth in dose-dependent manner. As shown in Fig. 5, fisetin micelles also indicated strong antitumor ability in xenograft mice carrying SKOV3. Most intriguing, as we have shown, although both fisetin and fisetin micelles have the same range of efficacy, fisetin micelles’ antitumor ability appeared to be marginally stronger than free fisetin. At the end of the experiment, we found that fisetin treatment at 50 mg/kg dosage led to 53.6% tumor growth inhibition. All of the data showed that fisetin can effectively decrease the tumor size and weight. The antitumor of fisetin micelles appeared to reach 70.7% inhibition after 21 days of treatment. Meanwhile, at the same dose of treatment, fisetin micelles seems to be more powerful than free fisetin.

**Ultrasound scan and the expression of apoptotic factors inside the tumor tissue**

The volume (V) of the solid tumors was measured by a philips HD11 ultrasound scanner (Philips Medical Systems, Best, The Netherlands equipped with an 11 MHz linear array transducer. The volume of solid tumors (expressed in millimeter) was documented in three dimensions, including length, width and height. The minimum diameter of the lesion that can be detected by ultrasound is only 0.01 cm. According to Fig. 6, the volume of tumor with treated fisetin/fisetin micelles is obviously smaller than other control groups. Meanwhile, the vessel number and size inside the tumor with fisetin/fisetin micelles treatment are less than control groups, the maximum blood vessel diameter was smaller than the untreated controls, although the statistical significance is not obvious. According to Fig. 6, at the concentration of 50 mg/kg, the blood vessel number is 2 and maximum blood diameter is 0.5 mm, the blood vessels number is less than control groups and vessel’s diameter is smaller than control (P < 0.05). As we know, Bcl-2 and Bax are pair of apoptosis proteins. It is well known that crosstalk between Bcl-2 and Bax intimately links to the fate of the cell. Bax itself can form a homologous. When the proportion of Bax/Bax is more than Bcl-2/Bax, it promotes the apoptosis of cells, whereas it can inhibit the apoptosis of cells. Followed with the increasing of the concentration of fisetin/fisetin micelles, Phosphorylation of ERK...
Fig. 3 (See legend on next page.)
was inhibited, which led to high expression of Bax and low expression of Bcl-2. In addition to activating the apoptotic pathway, fisetin/fisetin micelles also exerts its effects on ERK MARK (Data not shown). From Fig. 6c, data showed that Bcl-2 expression decreased inside the tumor tissue of xenograft treated with fisetin/fisetin micelles ($P < 0.05$), whereas Bax expression increased ($P < 0.05$), especially in the groups treated with high concentration of fisetin/fisetin micelles. The experiment indicated that Bcl-2 expression decreased and Bax expression increased in a dose-dependent manner after fesitin/fisetin micelles treatment. Fisetin/fisetin micelles treatment induced apoptosis of human ovarian cancer cells by mitochondrial pathway.

Fig. 3 FACS analysis for apoptotic incidence. a SKOV3 cells were treated with different concentrations of fisetin for 24 h. SKOV3 cells were treated with different concentrations of fisetin micelles for 24 h. b The bar chart shows percentage of apoptotic incidence compared to untreated control. Fisetin and Fisetin micelles induced SKOV3 cell apoptosis in a concentration-dependent manner. Error bars represent standard error of the mean (SEM) ($n = 3$) ($p < 0.01$, compared to control to be considered as significant)

Fig. 4 Fisetin/fisetin micelles induce cell apoptosis through mitochondrial pathway. Fisetin/fisetin micelles induce caspase activation and imbalance of Bax/Bcl-2 in treated SKOV3 cells. a Cells treated with different concentrations of fisetin for 24 h, meanwhile, at the same electric lane, sample from SKOV3 cells treated with the same concentration of fisetin micelles were loaded. DMSO (< 0.1%) diluted in saline was considered as control. GAPDH was used as a loading control. b Densitometric analysis was performed for Bcl-2, Bax, Cleaved-caspase-9 and Cleaved-caspase-3. Values were normalized to GAPDH. $P < 0.05$ compared to control
Discussion

Ovarian cancer is the most lethiferously gynecological cancer. Among the primary malignant tumors of the ovary, the epithelial malignant tumor is the main type. In the United States, the new incidence of ovarian cancer cases is about 22440 and 14080 death in 2017, which is occupied 5% of the total number of death populations, accounting for fifth of all cancer deaths in the United States [1]. With the development of modern medical technology, the efficiency of surgical treatment of ovarian cancer is significantly improved. Even though, however, the outcome of ovarian cancer is not satisfactory. To improve the survival rate and quality life in patients with ovarian cancer, especially in patients with advanced ovarian cancer stage, identification of effective, safe, non-toxic and low toxicity new drugs is particularly important [23–25]. Flavonoids are widely found in all kinds of plant pigments. Previously they are widely consumed by human beings. Fisetin (3,3', 4', 7 - 4 - hydroxy flavone) is a kind of flavonoids, which belongs to the polyphenolic compounds, extracted from the sumac plant stems and leaves of dietary. Flavonoid composition exists widely in all kinds of fruits and vegetables, such as apples, strawberries, persimmons, grapes, onions and cucumbers [26–30].

Pharmaceutical interest is increasing to discover natural compounds as well as their derivatives with anti-tumor activities [31]. In this regard, fisetin is a promising natural compound. Here we establish that it has cytotoxic effects in ovarian cancer cells by its ability to induce apoptosis and suppress angiogenesis. However, unmodified fisetin is of little clinical value due to low hydrophilicity. Attempts to increase the solubility by chemical modification always failed to maintain the anti-tumor effects. In present study, we developed fisetin micelles to improve its physical properties. Surprisingly, fisetin micelles demonstrated superior anti-tumor activities. In our study, we chose fisetin rotary evaporation with ethanol to prepare fisetin micelles due to the excellent properties of this products. The mPGE-PCL ends solve the problem of fisetin's poor water solubility. More than that, mPEG-PCL encapsulating fisetin has small particle size, narrow distribution, high EE, high DL, good homogeneity and gradually releasing behavior. We prepared fisetin micelles according to the previous protocols. Simply, Fisetin and MPEG-PCL micelles (fisetin:MPEG-PCL/wt = 1:9) were codissolved in dehydrated ethanol, then the mixed solution was evaporated at 60 °C. Fisetin finally distributed in the MPEG-PCL copolymer and formed a homogeneous amorphous coevaporation. The self-assembly process that coevaporation dissolved in a saline was called forming fisetin micelles. According to previous drug release study of fisetin micelles, the rate of fisetin released from micelles was much slower than that of free fisetin. The sustained-release property of fisetin micelles showed 73% release rate after 6 days of observation, while the free fisetin reached 93% of release rate. The releasing delay suggested that MPEG-PCL could minimize the

![Fig. 5 Fisetin and fisetin micelles inhibit tumor growth in a xenograft model of ovarian cancer.](image)
trauma to normal tissues and increase the accumulation in ovarian cancer tissues.

Fisetin micelles were more effective in suppressing tumor growth and prolonging survival than free fisetin. Cytotoxicity data showed that fisetin micelles had enhanced cytotoxicity compared to free fisetin ($\text{mean IC}_{50} = 48.2 \mu M$ versus $61.2 \mu M$, $p < 0.05$). Meanwhile, fisetin micelles treated cells showed stronger apoptosis induction ability, which was verified with TUNEL assay, flow cytometry and western blot analysis. It was indicated that uptake mechanisms of fisetin micelles could be connected to some sub cellular structures such as lysosomes. What’s more, the studies in vivo further indicated that fisetin micelles had a more efficient antitumor effect through the analysis of TUNEL assay, immunohistochemical detection and western blot.

We suspect the improvement could be explained by the following reasons. Firstly, from the in vitro drug-releasing model, we found that fisetin micelles pass through the blood vessel walls toward tissues at a relatively stable speed compared to free fisetin. The drug concentration in circulation and in plasma of cells could be maintained at a satisfied level to guarantee enough drug concentration around the tumor tissues area. The limited release to normal tissues limited the body immune attack to fisetin micelles, and, mPEG-PCL micelles were safe drug carrier with low cytotoxicity to normal cells. Secondly, fisetin micelles have smaller and more homogeneity size making transfer easier. Different from normal tissues, blood vessels inside tumor tissues have leaky vascular architecture, which means a big gap between endothelial cells as large as 20-2000 nm. The
gap seems easy to penetrate while might be a barrier for free fisetin.

**Conclusion**
Biodegradable fisetin micelles have been successfully structured and applied to the SKOV3 xenograft tumor model. Compared to free fisetin, fisetin micelles of small particle size and good homogeneity demonstrated lasting in vitro release behavior, cellular uptake, and enhanced cytotoxicity, as well as improved apoptosis induction. Fisetin micelles were considered to be potential antitumor drug after improvement of its solubility and bioavailability.

**Acknowledgments**
The authors do not have any acknowledgements.

**Funding**
The present study was supported by the Fund of the National Nature Science Foundations grant no. 81202387 and the Sichuan Province Science and Technology Plan Project no. 2013YF013/2014IV0213 and the Scientific Research Foundation of Sichuan University for outstanding young scholars no. 2013SCU04A22. The seventh new century education reform projects sponsored by Sichuan University no.(SCUY0709) Demonstration project of Chengdu science and technology (2015-HM02-00075-SF).

**Availability of data and materials**
Due to organizational restrictions the data will not be available.

**Authors’ contributions**
Conception and design: YBM, YF. Collection and assembly of patient data: XX, YY. All authors have read and approved the manuscript.

**Ethics approval and consent to participate**
All patients gave written informed consent for the study, which was approved by the Regional Administrative Authority.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of China.
2. Laboratory of Genetics, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of China.
3. Laboratory of Stem Cell & Tissue Engineering, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of China.
4. Laboratory of Obstetrics & Gynecology and Pediatric Diseases and Birth Defects of Ministry of Education, Chengdu, People’s Republic of China.
5. Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, No.24 South Section 1, Chengdu, Sichuan, People’s Republic of China.
6. Department of Obstetrics and Gynecology, Meishan City People’s Hospital, Meishan 620010, People’s Republic of China.
7. Department of Gynaecology and Obstetrics, ZIYang maternal and child health care hospital, West China Second University Union-hospital, Ziyang, People’s Republic of China.
8. Department of Gynaecology and Obstetrics, Zigong maternal and child health care hospital, Zigong, People’s Republic of China.
9. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Received: 21 August 2017 Accepted: 7 February 2018
Published online: 15 March 2018

**References**
1. Segel RL, Miller KD, Jermal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2. Li W, Cai JH, Zhang J, Tang YX, Wan L. Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Int J Mol Sci. 2012;13:9741–53.
3. Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011;10:255–68.
4. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and p38 MAPK signaling pathways: Carcinogenesis. 2009;30:360–7.
5. Li Z, Guo X, Guan J. An oxygen release system to augment cardiac progenitor cell survival and differentiation under hypoxic condition. Biomaterials. 2012;33:9144–9154.
6. Chen WS, Lee YJ, Yu YC, Hao CH, Chen JN, Yen JH, Yu SH, Tsai YJ, Chiu SJ. Enhancement of p53-mutant human colorectal cancer cells radio-sensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys. 2010;77:1527–35.
7. Ying TH, Yang SF, Tsai SJ, Hsieh SC, Huang YC, Bau DT, Hsieh YH. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8–caspase-3-dependent pathway. Arch Toxicol. 2012;86:263–73.
8. Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006;47:1644–77.
9. Crouzier A, Bums J, Aziz AA, Stewart WA, Rabiahs MS, Jenkins GJ, Edwards CA, Lean ME. Antioxidant flavonoids from fruits, vegetables and beverages: measurements and bioavailability. Biol Res. 2000;33:79–88.
10. Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Sueuruma M, Kawase I, Tanaka T. Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol. 2003;111:299–306.
11. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, Yang LL. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-Hep-1. Arch Toxicol. 2002;76:351–9.
12. Haddad AQ, Venkateswaran V, Wiswanathan L, Teahan SJ, Fleschner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9:66–76.
13. Haddad AQ, Fleschner N, Nelson C, Saour B, Musquera M, Venkateswaran V, Klotz L. Antiproliferative mechanisms of the flavonoids 2’,4’-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer. 2010b;62:668–81.
14. Chien CS, Shen KH, Huang JS, Ko SC, Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem. 2010;333:169–80.
15. Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis. 2010;31:1424–33.
16. Toulil YS, Azezli N, Boulineau F, Saighi H, Regazzetti A, Scherman D, Chabot GG. Fisetin disposition and metabolism in mice: identification of genidol as an active metabolite. Biochem Pharmacol. 2011;82:1731–9.
17. Anso E, Zuazo A, Irgogcy M, Urdaci MC, Rozout A, Martinez-Koujo J. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HH-1 dependent mechanism. Biochem Pharmacol. 2010;79:1600–9.
18. Wu MY, Hung SK, Fu SL. Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity. J Agric Food Chem. 2011;59:10496–1054.
19. Kim JY, Jeon YK, Jeon W, Nam MJ. Fisetin induces apoptosis in Huh-7 cells via downregulation of BcIR8 and Bcl2L2. Food Chem Toxicol. 2010;48:2259–64.
20. Chen Y, Wu Q, Song L, He T, Li Y, Li L, Su W, Liu L, Qian Z, Gong C. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl Mater Interfaces. 2015;7:534–42.

21. Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J. Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer. Mol Cancer Ther. 2017. https://doi.org/10.1158/1535-7163.MCT-17-0561.

22. Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016 Feb;18:1227–46.

23. Echarri GMJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when. Oncology (Williston Park). 2011;25:156–65.

24. Li QQ, Lee RX, Liang H, Zhong Y, Reed E. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 2013;30:424.

25. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

26. Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008;68:8555–63.

27. Kozics K, Valovicova Z, Slamenova D. Structure of flavonoids influences the degree inhibition of benzo(a)pyrene-induced DNA damage and micronuclei in HepG2 cells. Neoplasma. 2011;58:516–24.

28. Katalinić M, Rusak G, Domačinović BI, Sinko G, Jelić D, Antolović R, Kovarik Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2010;45:186–92.

29. López-Lázaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res. 2010;696:41–7.

30. Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, Tian B. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2011;108:88–93.

31. Khan N, Afaq F, Khuroo FH, Mustafa AV, Suh Y, Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer. 2012;130:1695–705.